172 related articles for article (PubMed ID: 17720512)
1. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a US physician perspective.
Kasiske BL
Am J Kidney Dis; 2007 Sep; 50(3):354-7. PubMed ID: 17720512
[No Abstract] [Full Text] [Related]
2. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.
Lazarus JM; Hakim RM
Am J Kidney Dis; 2007 Sep; 50(3):366-70. PubMed ID: 17720515
[No Abstract] [Full Text] [Related]
3. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective.
Cohen JT; Neumann PJ
Am J Kidney Dis; 2007 Sep; 50(3):362-5. PubMed ID: 17720514
[No Abstract] [Full Text] [Related]
4. Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview.
Weiner DE; Levey AS
Am J Kidney Dis; 2007 Sep; 50(3):349-53. PubMed ID: 17720511
[No Abstract] [Full Text] [Related]
5. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe.
Macdougall IC
Am J Kidney Dis; 2007 Sep; 50(3):358-61. PubMed ID: 17720513
[No Abstract] [Full Text] [Related]
6. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
[TBL] [Abstract][Full Text] [Related]
7. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
[TBL] [Abstract][Full Text] [Related]
8. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis: the authors respond.
Thamer M; Zhang Y; Kaufman J; Cotter D; Hernán MA
Am J Kidney Dis; 2007 Oct; 50(4):538-41. PubMed ID: 17900452
[No Abstract] [Full Text] [Related]
9. Epoetin dosing and dialysis facility ownership.
Kliger AS; Nissenson AR
JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
[No Abstract] [Full Text] [Related]
10. Epoetin dosing and dialysis facility ownership.
Regidor DL; Kalantar-Zadeh K; Kovesdy CP
JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
[No Abstract] [Full Text] [Related]
11. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
12. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
[TBL] [Abstract][Full Text] [Related]
13. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
[TBL] [Abstract][Full Text] [Related]
14. Use of epoetin in chronic renal failure.
Coyne DW
JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
[No Abstract] [Full Text] [Related]
15. Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians?
Hirth RA; Turenne MN; Wheeler JR; Ma Y; Messana JM
Med Care; 2010 Aug; 48(8):726-32. PubMed ID: 20613666
[TBL] [Abstract][Full Text] [Related]
16. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
Holloway M
Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
[TBL] [Abstract][Full Text] [Related]
17. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
Hayslip D
Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
[TBL] [Abstract][Full Text] [Related]
18. Serratia liquefaciens infections at a hemodialysis center.
Kremer K
N Engl J Med; 2001 Sep; 345(12):922; author reply 922-3. PubMed ID: 11565531
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
Arroliga AC; Guntupalli KK; Beaver JS; Langholff W; Marino K; Kelly K
Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
[TBL] [Abstract][Full Text] [Related]
20. Translating epoetin research into practice: the role of government and the use of scientific evidence.
Lazarus JM; Hakim RM
Nephrol News Issues; 2006 Dec; 20(13):12, 22. PubMed ID: 17168053
[No Abstract] [Full Text] [Related]
[Next] [New Search]
